Recombinant Anti-CD19 x Anti-CD3 Bispecific Antibody (Fv-IgG) is an appended IgG format, which has 2+2 antigen-binding valency. This dual variable domain IgG is generated by appending variable domains of an anti-CD19 IgG with similar domains from an anti-CD3 antibody via short peptide linkers, or vice versa. This BsAb can retarget T cells to tumor cells. It is designed for the research of B cell lymphoma; Follicular lymphoma; Leukemia therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY